Chardan Capital restated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN – Free Report) in a research report released on Monday morning,Benzinga reports. They currently have a $38.00 target price on the stock. Other analysts also recently issued reports about the company. Stifel Nicolaus increased their price target on Dyne Therapeutics from $36.00 to […]

Clene (NASDAQ:CLNN – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a research note issued on Thursday,Benzinga reports. They currently have a $23.00 price objective on the stock. D. Boral Capital’s price target points to a potential upside of 288.51% from the company’s current price. Several […]

D. Boral Capital reaffirmed their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI – Free Report) in a research report report published on Monday morning,Benzinga reports. They currently have a $19.00 price target on the stock. TRVI has been the topic of several other reports. Oppenheimer increased their target price on shares of Trevi Therapeutics […]

D. Boral Capital reissued their buy rating on shares of NeuroSense Therapeutics (NASDAQ:NRSN – Free Report) in a research report report published on Monday morning,Benzinga reports. D. Boral Capital currently has a $14.00 target price on the stock. NRSN has been the subject of a number of other research reports. Wall Street Zen upgraded NeuroSense […]

Orchestra BioMed (NASDAQ:OBIO – Get Free Report)‘s stock had its “buy” rating reissued by Chardan Capital in a research note issued on Thursday,Benzinga reports. They presently have a $20.00 price objective on the stock. Chardan Capital’s target price points to a potential upside of 356.62% from the company’s previous close. OBIO has been the topic […]